Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)

Johns Hopkins Bloomberg School of Public Health, United States. Electronic address: .
Vaccine (Impact Factor: 3.62). 10/2012; 30(50). DOI: 10.1016/j.vaccine.2012.09.074
Source: PubMed


Adverse events following immunization (AEFI) reported to the national Vaccine Adverse Event Reporting System (VAERS) represent true causally related events, as well as events that are temporally, but not necessarily causally related to vaccine. OBJECTIVE: We sought to determine if the causal relationships between the vaccine and the AEFI reported to VAERS could be assessed through expert review. DESIGN: A stratified random sample of 100 VAERS reports received in 2004 contained 13 fatal cases, 19 cases with non-fatal disabilities, 39 other serious non-fatal cases and 29 non-serious cases. Experts knowledgeable about vaccines and clinical outcomes, reviewed each VAERS report and available medical records. MAIN OUTCOME MEASURES: Modified World Health Organization criteria were used to classify the causal relationship between vaccines and AEFI as definite, probable, possible, unlikely or unrelated. Five independent reviewers evaluated each report. If they did not reach a majority agreement on causality after initial review, the report was discussed on a telephone conference to achieve agreement. RESULTS: 108 AEFIs were identified in the selected 100 VAERS reports. After initial review majority agreement was achieved for 83% of the AEFI and 17% required further discussion. In the end, only 3 (3%) of the AEFI were classified as definitely causally related to vaccine received. Of the remaining AEFI 22 (20%) were classified as probably and 22 (20%) were classified as possibly related to vaccine received; a majority (53%) were classified as either unlikely or unrelated to a vaccine received. CONCLUSIONS: Using VAERS reports and additional documentation, causality could be assessed by expert review in the majority of VAERS reports. Assessment of VAERS reports identified that causality was thought to be probable or definite in less than one quarter of reports, and these were dominated by local reactions, allergic reactions, or symptoms known to be associated with the vaccine administered.

Download full-text


Available from: Christine Casey, Sep 18, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: To analyze the epidemiological features of adverse events following immunization (AEFI) in Henan Province, China and to evaluate the safety of vaccines currently used in Henan. The AEFI cases reported in Henan from January 1, 2010 to December 31, 2011 were collected through the China Surveillance System of Information on National Immunization Program. The descriptive method was used for epidemiological analysis. A total of 2415 cases of AEFI were reported in Henan from January 1, 2010 to December 31, 2011, and 1238 (51.26%) of them were found in Zhengzhou, Luoyang, and Jiaozuo cities. The male-to-female ratio was 1.32:1. Seven hundred and ninety-nine (33.08%) of these cases were less than one year old. Measles vaccine and DPT vaccine (against diphtheria, pertussis, and tetanus) were the main causes of AEFI, contributing to 61.24% of cases; the incidence rates of AEFI among people receiving measles and DPT vaccines were 30.3/105 and 5.0/105, respectively. 1528 cases (63.27%) developed AEFI after the first dose of vaccination. Inflammation and allergic symptoms were the predominant adverse effects caused by the top 5 vaccines AEFI-causing vaccines, and the clinical manifestations were significantly different among AEFI cases caused by different vaccines (χ2=304.5, P<0.001). Among the 2415 AEFI cases, 1946 (80.58%) had common adverse reaction, 348 (14.41%) had rare adverse reaction, 98 (4.06%) had coupling disease, 13 (0.51%) had psychogenic reaction, and 10 (0.41%) had reaction for unknown reasons. The prognosis of most AEFI cases was good, with a cure rate as high as 90.64%. AEFI occurs mostly in young children and after the first dose of vaccination. This should be brought to the attention of vaccination service personnel and the children's parents.
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 06/2013; 15(6):466-71. DOI:10.7499/j.issn.1008-8830.2013.06.017
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Medication errors are an important public health problem and the subgroup of vaccination errors is relatively understudied. We characterized vaccination error reports to the Vaccine Adverse Event Reporting System (VAERS), a U.S. passive surveillance system for vaccine adverse events (AEs). METHODS: Signs and symptoms of AEs described in VAERS reports and reported medical errors are coded using the Medical Dictionary for Regulatory Activities (MedDRA). We searched VAERS for U.S. reports of vaccination errors from 2000-2011 using 39 MedDRA medical error coding terms and categorized them into 11 error groups. We performed manual review of selected reports and available medical records. RESULTS: Of the 255,528 reports received by VAERS from 2000-2011, we identified 13,137 (5.1% ) vaccination error reports. The number of annual vaccination error reports increased from 10 reports in 2000 to 1,396 in 2011, peaking at 2,696 in 2008. Of the vaccination error reports, 8813 (67%) reported the error without any AE while 4,324 (32.9%) documented an AE. Among these reports the most common AEs were injection site erythema (n=583, 13.5%), fever (n=495, 11.4%) and injection site pain (n=468, 10.8%). The most common vaccination error reported was inappropriate schedule (i.e. wrong age, wrong schedule) (n=3,886, 29.6%), most often described for pediatric rotavirus vaccines (n=620, 16%). The second most common vaccination error was wrong vaccine administered (n=2,693, 20.5%). In a random sample of 100 reports of wrong vaccine administered, the most common mix-ups involved similar or related vaccines (i.e. Varicella and Zoster, pediatric DTaP and adult Tdap) in vaccination settings that served both children and adults. We identified an unexpected vaccination error: 25 reports of rotavirus vaccine eye splashes affecting mainly healthcare providers (16 associated with ocular symptoms). Cluster reports occurring in multiple individuals (range 2-500 persons) at the same vaccination location and date were noted 208 times; the most common error for clusters was expired drug administered. CONCLUSIONS: Although VAERS data have limitations of passive surveillance, the data show that potentially preventable vaccination errors have occurred since 2000 in individuals and in clusters. The most common vaccination errors, inappropriate schedule and wrong vaccine, as well as unexpected rotavirus eye splashes, may be prevented with education or packaging changes. Even though most vaccination errors are not temporally associated with an adverse health event, errors potentially could cause adverse events, incur additional costs, inconvenience patients and impact confidence in vaccination programs. Prevention strategies should be considered and evaluated.
    2013 Council of State and Territorial Epidemiologists Annual Conference; 06/2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Comprehensive surveillance of adverse events following immunization (AEFI) is required to detect potential serious adverse events that may not be identified in prelicensure vaccine trials. Surveillance systems have traditionally been passive, relying upon spontaneous reporting, but increasingly active surveillance and supplemental strategies are being incorporated into vaccine safety programs. These include active screening for targeted conditions of interest (e.g., hospitalization), monitoring of new data sources and real-time methodologies to detect changes in vaccine safety data in these sources. The role of improved causality assessment in AEFI surveillance is discussed, with its important role in determining whether a temporal association may have occurred by chance alone. Strong local vaccine safety networks are required to support national immunization programs, with recent progress in developing a framework for low- and middle-income countries. Global collaboration is increasingly required to address challenges in active AEFI surveillance, particularly for rare serious adverse events.
    Expert Review of Vaccines 12/2013; 13(2). DOI:10.1586/14760584.2014.866895 · 4.21 Impact Factor
Show more